Seattle biotech Atossa Therapeutics eyes acquisition of unnamed company
July 11, 2022 at 17:25 PM EDT
Atossa has paid $3 million for exclusive rights to negotiate the deal. The target company focuses on a form of cancer treatment.
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart Quotes delayed at least 20 minutes. By accessing this page, you agree to the following Privacy Policy and Terms and Conditions. |
|